As Introduced

133rd General Assembly

Regular Session 2019-2020

H. B. No. 341

Representative Ginter

Cosponsors: Representatives Seitz, Blair, Lightbody, Koehler

A BILL

ГО	amend sections 4723.52, 4729.45, 4729.553,	1
	4730.56, and 4731.83 of the Revised Code	2
	regarding the administration of drugs for	3
	addiction treatment.	4

BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF OHIO:

Section 1. That sections 4723.52, 4729.45, 4729.553,	5
4730.56, and 4731.83 of the Revised Code be amended to read as	6
follows:	7
Sec. 4723.52. (A) As used in this section:	8
(1) "Community addiction services provider" has the same	9
meaning as in section 5119.01 of the Revised Code.	10
(2) "Medication-assisted treatment" has the same meaning as in section 340.01 of the Revised Code.	11 12
(B) An advanced practice registered nurse shall comply	13
with section 3719.064 of the Revised Code and rules adopted	14
under section 4723.51 of the Revised Code when treating a	15
patient for addiction with medication-assisted treatment or	16
proposing to initiate such treatment	17

(C) An advanced practice registered nurse who fails to	18
comply with this section shall treat not more than thirty	19
patients at any one time with medication-assisted treatment even	20
if the facility or location at which the treatment is provided	21
is either of the following:	22
(1) Exempted by divisions (B)(2)(a) to (d) or (i) of	23
section 4729.553 of the Revised Code from being required to	24
possess a category III terminal distributor of dangerous drugs	25
license with an office-based opioid treatment classification;	26
(2) A community addiction services provider that provides	27
alcohol and drug addiction services that are certified by the	28
department of mental health and addiction services under section	29
5119.36 of the Revised Code.	30
Sec. 4729.45. (A) As used in this section, "physician"	31
means an individual authorized under Chapter 4731. of the	32
Revised Code to practice medicine and surgery or osteopathic	33
medicine and surgery.	34
(B)(1) Subject to division (C) of this section, a	35
pharmacist licensed under this chapter may administer by	36
injection any of the following drugs as long as the drug that is	37
to be administered has been prescribed by a physician and the	38
individual to whom the drug was prescribed has an ongoing	39
physician-patient relationship with the physician:	40
(a) An opioid antagonist A drug used for treatment of drug	41
addiction and administered in a long-acting or extended-release	42
form;	43
(b) An antipsychotic drug administered in a long-acting or	44
<pre>extended-release form;</pre>	45
(c) Hydroxyprogesterone caproate;	46

(d) Medroxyprogesterone acetate;	47
(e) Cobalamin.	48
(2) As part of engaging in the administration of drugs by	49
injection pursuant to this section, a pharmacist may administer	50
epinephrine or diphenhydramine, or both, to an individual in an	51
emergency situation resulting from an adverse reaction to a drug	52
administered by the pharmacist.	53
(C) To be authorized to administer drugs pursuant to this	54
section, a pharmacist must do all of the following:	55
(1) Successfully complete a course in the administration	56
of drugs that satisfies the requirements established by the	57
state board of pharmacy in rules adopted under division (H)(1)	58
(a) of this section;	59
(2) Receive and maintain certification to perform basic	60
life-support procedures by successfully completing a basic life-	61
support training course that is certified by the American red	62
cross or American heart association or approved by the state	63
board of pharmacy;	64
(3) Practice in accordance with a protocol that meets the	65
requirements of division (F) of this section.	66
(D) Each time a pharmacist administers a drug pursuant to	67
this section, the pharmacist shall do all of the following:	68
(1) Obtain permission in accordance with the procedures	69
specified in rules adopted under division (H) of this section	70
and comply with the following requirements:	71
(a) Except as provided in division (D)(1)(c) of this	72
section, for each drug administered by a pharmacist to an	73
individual who is eighteen years of age or older, the pharmacist	74

shall obtain permission from the individual.	75
(b) For each drug administered by a pharmacist to an	76
individual who is under eighteen years of age, the pharmacist	77
shall obtain permission from the individual's parent or other	78
person having care or charge of the individual.	79
(c) For each drug administered by a pharmacist to an	80
individual who lacks the capacity to make informed health care	81
decisions, the pharmacist shall obtain permission from the	82
person authorized to make such decisions on the individual's	83
behalf.	84
(2) In the case of an opioid antagonist a drug described	85
in division (B) $\underline{(1)(a)}$ of this section, obtain in accordance with	86
division (E) of this section test results indicating that it is	87
appropriate to administer the drug to the individual if either	88
of the following is to be administered:	89
(a) The initial dose of the drug;	90
(b) Any subsequent dose, if the administration occurs more	91
than thirty days after the previous dose of the drug was	92
administered.	93
(3) Observe the individual to whom the drug is	94
administered to determine whether the individual has an adverse	95
reaction to the drug;	96
(4) Notify the physician who prescribed the drug that the	97
drug has been administered to the individual.	98
(E) A pharmacist may obtain the test results described in	99
division (D)(2) of this section in either of the following ways:	100
(1) From the physician;	101

(2) By ordering blood and urine tests for the individual	102
to whom the opioid antagonist drug is to be administered.	103
If a pharmacist orders blood and urine tests, the	104
pharmacist shall evaluate the results of the tests to determine	105
whether they indicate that it is appropriate to administer the	106
opioid antagonist drug. A pharmacist's authority to evaluate	107
test results under this division does not authorize the	108
pharmacist to make a diagnosis.	109
(F) All of the following apply with respect to the	110
protocol required by division (C)(3) of this section:	111
(1) The protocol must be established by a physician who	112
has a scope of practice that includes treatment of the condition	113
for which the individual has been prescribed the drug to be	114
administered.	115
(2) The protocol must satisfy the requirements established	116
in rules adopted under division (H)(1)(b) of this section.	117
(3) The protocol must do all of the following:	118
(a) Specify a definitive set of treatment guidelines;	119
(b) Specify the locations at which a pharmacist may engage	120
in the administration of drugs pursuant to this section;	121
(c) Include provisions for implementing the requirements	122
of division (D) of this section, including for purposes of	123
division (D)(3) of this section provisions specifying the length	124
of time and location at which a pharmacist must observe an	125
individual who receives a drug to determine whether the	126
individual has an adverse reaction to the drug;	127
(d) Specify procedures to be followed by a pharmacist when	128
administering epinephrine, diphenhydramine, or both, to an	129

individual who has an adverse reaction to a drug administered by the pharmacist.	130 131
(G) A pharmacist shall not do either of the following:	132
(1) Engage in the administration of drugs pursuant to this section unless the requirements of division (C) of this section	133 134
have been met;	135
(2) Delegate to any person the pharmacist's authority to engage in the administration of drugs pursuant to this section.	136 137
(H)(1) The state board of pharmacy shall adopt rules to	138
implement this section. The rules shall be adopted in accordance	139
with Chapter 119. of the Revised Code and include all of the following:	140 141
(a) Requirements for courses in administration of drugs;	142
(b) Requirements for protocols to be followed by	143
pharmacists in administering drugs pursuant to this section;	144
(c) Procedures to be followed by a pharmacist in obtaining	145
permission to administer a drug to an individual.	146
(2) The board shall consult with the state medical board	147
before adopting rules regarding requirements for protocols under	148
this section.	149
Sec. 4729.553. (A) As used in this section:	150
(1) "Advanced practice registered nurse" has the same_	151
meaning as in section 4723.01 of the Revised Code.	152
(2) "Controlled substance" has the same meaning as in	153
section 3719.01 of the Revised Code.	154
(2) (3) "Hospital" means a hospital registered with the	155
department of health under section 3701.07 of the Revised Code.	156

$\frac{(3)}{(4)}$ "Office-based opioid treatment" means the	157
treatment of opioid dependence or addiction using a controlled	158
substance.	159
(5) "Physician" means an individual who is authorized	160
under Chapter 4731. of the Revised Code to practice medicine and	161
surgery or osteopathic medicine and surgery.	162
(6) "Physician assistant" means an individual who is	163
licensed under Chapter 4730. of the Revised Code.	164
(B)(1) Except as provided in division divisions (B)(2) and	165
(3) of this section, no person shall knowingly operate a	166
facility, clinic, or other location where a prescriber provides	167
office-based opioid treatment to more than thirty patients or	168
that meets any other identifying criteria established in rules	169
adopted under this section without holding a category III	170
terminal distributor of dangerous drugs license with an office-	171
based opioid treatment classification.	172
(2) Division (B)(1) of this section does not apply to any	173
of the following:	174
(a) A hospital;	175
(b) A facility for the treatment of opioid dependence or	176
addiction that is operated by a hospital;	177
(c) A physician practice owned or controlled, in whole or	178
in part, by a hospital or by an entity that owns or controls, in	179
whole or in part, one or more hospitals;	180
(d) A facility that conducts only clinical research and	181
uses controlled substances in studies approved by a hospital-	182
based institutional review board or an institutional review	183
board that is accredited by the association for the	184

accreditation of human research protection programs, inc.;	185
(e) A facility that holds a category III terminal	186
distributor of dangerous drugs license in accordance with	187
section 4729.54 of the Revised Code for the purpose of treating	188
drug dependence or addiction as part of an opioid treatment	189
program and is the subject of a current, valid certification	190
from the substance abuse and mental health services	191
administration of the United States department of health and	192
human services pursuant to 42 C.F.R. 8.11;	193
(f) A program or facility that holds a license or	194
certification issued by the department of mental health and	195
addiction services under Chapter 5119. of the Revised Code if	196
the license or certification is approved by the state board of	197
pharmacy;	198
(g) A federally qualified health center or federally	199
qualified health center look-alike, as defined in section	200
3701.047 of the Revised Code;	201
(h) A state or local correctional facility, as defined in	202
section 5163.45 of the Revised Code;	203
(i) A place in which patients are treated for opioid	204
dependence or addiction through direct administration by a	205
physician, physician assistant, or advanced practice registered	206
nurse of drugs that are used for treatment of opioid dependence	207
or addiction and are not dispensed to patients for self-	208
administration;	209
(j) Any other facility specified in rules adopted under	210
this section.	211
(3) A patient who receives treatment for opioid dependence	212
or addiction through direct administration of a drug by a	213

physician, physician assistant, or advanced practice registered	214
nurse shall not be included in determining whether more than	215
thirty patients are being provided office-based opioid treatment	216
in a particular facility, clinic, or other location that is	217
subject to division (B) (1) of this section.	218
(C) To be eligible to receive a license as a category III	219
terminal distributor of dangerous drugs with an office-based	220
opioid treatment classification, an applicant shall submit	221
evidence satisfactory to the <u>state</u> board <u>of pharmacy</u> that the	222
applicant's office-based opioid treatment will be operated in	223
accordance with the requirements specified in division (D) of	224
this section and that the applicant meets any other applicable	225
requirements of this chapter.	226
If the board determines that an applicant meets all of the	227
requirements, the board shall issue to the applicant a license	228
as a category III terminal distributor of dangerous drugs with	229
an office-based opioid treatment classification.	230
(D) The holder of a category III terminal distributor	231
license with an office-based opioid treatment classification	232
shall do all of the following:	233
(1) Be in control of a facility that is owned and operated	234
solely by one or more physicians—authorized under Chapter 4731.	235
of the Revised Code to practice medicine and surgery or	236
osteopathic medicine and surgery, unless the state board of	237
pharmacy waives this requirement for the holder;	238
(2) Comply with the requirements for conducting office-	239
based opioid treatment, as established by the state medical	240
board in rules adopted under section 4731.056 of the Revised	241
Code:	242

(3) Require any person with ownership of the facility to	243
submit to a criminal records check in accordance with section	244
4776.02 of the Revised Code and send the results of the criminal	245
records check directly to the state board of pharmacy for review	246
and decision under section 4729.071 of the Revised Code;	247
(4) Require each person employed by or seeking employment	248
with the facility to submit to a criminal records check in	249
accordance with section 4776.02 of the Revised Code;	250
(5) Ensure that a person is not employed by the facility	251
if the person, within the ten years immediately preceding the	252
date the person applied for employment, was convicted of or	253
pleaded guilty to either of the following, unless the state	254
board of pharmacy permits the person to be employed by waiving	255
this requirement for the facility:	256
(a) A theft offense, described in division (K)(3) of	257
section 2913.01 of the Revised Code, that would constitute a	258
felony under the laws of this state, any other state, or the	259
United States;	260
(b) A felony drug offense, as defined in section 2925.01	261
of the Revised Code.	262
(6) Maintain a list of each person with ownership of the	263
facility and notify the state board of pharmacy of any change to	264
that list.	265
(E) No person subject to licensure as a category III	266
terminal distributor of dangerous drugs with an office-based	267
opioid treatment classification shall knowingly fail to remain	268
in compliance with the requirements of division (D) of this	269
section and any other applicable requirements of this chapter.	270
(F) The state board of pharmacy may impose a fine of not	271

H. B. No. 341 Page 11 As Introduced

more than five thousand dollars on a person who violates	272
-	
division (B) or (E) of this section. A separate fine may be	273
imposed for each day the violation continues. In imposing the	274
fine, the board's actions shall be taken in accordance with	275
Chapter 119. of the Revised Code.	276
(G) The state board of pharmacy shall adopt rules as it	277
considers necessary to implement and administer this section.	278
The rules shall be adopted in accordance with Chapter 119. of	279
the Revised Code.	280
Sec. 4730.56. (A) As used in this section:	281
(1) "Community addiction services provider" has the same	282
meaning as in section 5119.01 of the Revised Code.	283
(2) "Medication-assisted treatment" has the same meaning	284
as in section 340.01 of the Revised Code.	285
(B) A physician assistant shall comply with section	286
3719.064 of the Revised Code and rules adopted under section	287
4730.55 of the Revised Code when treating a patient with	288
medication-assisted treatment or proposing to initiate such	289
treatment.	290
(C) A physician assistant who fails to comply with this	291
section shall treat not more than thirty patients at any one	292
time with medication-assisted treatment even if the facility or	293
location at which the treatment is provided is either of the	294
following:	295
(1) Exempted by divisions (B)(2)(a) to (d) or (i) of	296
section 4729.553 of the Revised Code from being required to	297
possess a category III terminal distributor of dangerous drugs	298
license with an office-based opioid treatment classification;	299

H. B. No. 341 Page 12 As Introduced

(2) A community addiction services provider that provides	300
alcohol and drug addiction services that are certified by the	301
department of mental health and addiction services under section	302
5119.36 of the Revised Code.	303
Sec. 4731.83. (A) As used in this section:	304
(1) "Medication-assisted treatment" has the same meaning	305
as in section 340.01 of the Revised Code.	306
(2) "Physician" means an individual authorized by this	307
chapter to practice medicine and surgery or osteopathic medicine	308
and surgery.	309
(B) A physician shall comply with section 3719.064 of the	310
Revised Code and rules adopted under section 4731.056 of the	311
Revised Code when treating a patient with medication-assisted	312
treatment or proposing to initiate such treatment.	313
(C) A physician who fails to comply with this section	314
shall treat not more than thirty patients at any one time with	315
medication-assisted treatment even if the facility or location	316
at which the treatment is provided is either of the following:	317
(1) Exempted by divisions (B)(2)(a) to (d) or (i) of	318
section 4729.553 of the Revised Code from being required to	319
possess a category III terminal distributor of dangerous drugs	320
license with an office-based opioid treatment classification;	321
(2) A community addiction services provider that provides	322
alcohol and drug addiction services that are certified by the	323
department of mental health and addiction services under section	324
5119.36 of the Revised Code.	325
Section 2. That existing sections 4723.52, 4729.45,	326
4729 553. 4730 56. and 4731 83 of the Revised Code are hereby	327

repealed.	328
Section 3. Section 4729.553 of the Revised Code is	329
presented in this act as a composite of the section as amended	330
by both Sub. H.B. 101 and Sub. S.B. 229 of the 132nd General	331
Assembly. The General Assembly, applying the principle stated in	332
division (B) of section 1.52 of the Revised Code that amendments	333
are to be harmonized if reasonably capable of simultaneous	334
operation, finds that the composite is the resulting version of	335
the section in effect prior to the effective date of the section	336
as presented in this act.	337